Cocrystal Pharma (COCP) Income from Continuing Operations (2010 - 2026)
Cocrystal Pharma (COCP) posted Income from Continuing Operations of 2334000.0 for Q1 2026, down 1.52% sequentially from 2299000.0 in Q4 2025, and down 1.3% YoY from 2364791.56 in Q1 2025.
Cocrystal Pharma (COCP) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Income from Continuing Operations for 17 years, with the latest figure at 2334000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 1.3% year-over-year to 2334000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9340000.0 (up 51.65% YoY) and the FY2025 annual result came in at 9693000.0, up 48.07% from the prior year.
- Income from Continuing Operations slipped to 2334000.0 in Q1 2026 per COCP's latest filing, from 2299000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2299000.0 in Q4 2025 and troughed at 24454000.0 in Q2 2022.
- A 5-year average of 5308823.53 and a median of 4486000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 529.45% in 2022, then soared 81.51% in 2023.
- Over 5 years, Income from Continuing Operations stood at 4502000.0 in 2022, then grew by 0.36% to 4486000.0 in 2023, then increased by 11.35% to 3977000.0 in 2024, then soared by 42.19% to 2299000.0 in 2025, then dropped by 1.52% to 2334000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2334000.0, 2299000.0, and 2331000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | -3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.70 Mn |
| Mar 31, 2026 | -2.33 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -2.33 Mn |
| Jun 30, 2025 | -2.38 Mn |
| Mar 31, 2025 | -2.30 Mn |
| Dec 31, 2024 | -3.98 Mn |
| Sep 30, 2024 | -5.46 Mn |
| Jun 30, 2024 | -7.58 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Dec 31, 2023 | -4.49 Mn |
| Sep 30, 2023 | -4.12 Mn |
| Jun 30, 2023 | -4.52 Mn |
| Mar 31, 2023 | -5.17 Mn |
| Dec 31, 2022 | -4.50 Mn |
| Sep 30, 2022 | -5.71 Mn |
| Jun 30, 2022 | -24.45 Mn |
| Mar 31, 2022 | -4.69 Mn |
| Dec 31, 2021 | -3.70 Mn |
| Sep 30, 2021 | -4.01 Mn |